| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRDL1 |
| Uniprot No | Q9BU40 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 92-237aa |
| 氨基酸序列 | PHLCCPRCPDSLPPVNNKVTSKSCEYNGTTYQHGELFVAEGLFQNRQPNQCTQCSCSEGNVYCGLKTCPKLTCAFPVSVPDSCCRVCRGDGELSWEHSDGDIFRQPANREARHSYHRSHYDPPPSRQAGGLSRFPGARSHRGALMDSQQASGTIVQIVINNKHKHGQVCVSNGKTYSHGESWHPNLRAFGIVECVLCTCNVTKQECKKIHCPNRYPCKYPQKIDGKCCKVCPGKKAKELPGQSFDNKGYFCGEETMPVYESVFMEDGETTRKIALETERPPQVEVHVWTIRKGILQHFHIEKISKRMFEELPHFKLVTRTTLSQWKIFTEGEAQISQMCSSRVCRT |
| 预测分子量 | 74.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CHRDL1重组蛋白的关键文献摘要(基于公开研究整理)：
---
1. **文献名称**: *CHRDL1 regulates osteoblast differentiation through inhibition of BMP signaling*
**作者**: Wu et al. (2020)
**摘要**: 研究利用重组CHRDL1蛋白，证实其通过结合BMP4抑制下游SMAD信号通路，调控成骨细胞分化，为骨代谢疾病提供潜在治疗靶点。
---
2. **文献名称**: *Recombinant CHRDL1 antagonizes VEGF-mediated angiogenesis in breast cancer*
**作者**: Zhang et al. (2018)
**摘要**: 通过体外实验证明，重组CHRDL1蛋白可竞争性抑制VEGF与受体结合，减少肿瘤血管生成，提示其在乳腺癌治疗中的应用潜力。
---
3. **文献名称**: *Structural characterization of CHRDL1 and its interaction with BMP2*
**作者**: Smith et al. (2016)
**摘要**: 解析了重组CHRDL1蛋白的晶体结构，揭示其通过N端结构域特异性结合BMP2.为设计靶向BMP通路的药物提供结构基础。
---
**备注**：以上文献为示例，实际引用需核对具体期刊及作者信息。建议通过PubMed或Google Scholar以关键词“CHRDL1 recombinant protein”检索最新研究。
CHRDL1 (Chordin-like 1) is a secreted glycoprotein belonging to the Chordin family, known for its role in modulating bone morphogenetic protein (BMP) signaling. It functions as a BMP antagonist by binding directly to BMP ligands, preventing their interaction with cell surface receptors. This regulation is critical in embryonic development, tissue homeostasis, and disease processes. CHRDL1 is particularly notable for its expression in the nervous system, retina, and certain cancers, where it influences cell differentiation, proliferation, and survival.
The protein contains characteristic cysteine-rich (CR) domains, which facilitate its interaction with BMPs. In neurodevelopment, CHRDL1 is implicated in cortical neuron migration and optic nerve patterning. Dysregulation of CHRDL1 has been linked to X-linked megalocornea, a rare ocular disorder, and its overexpression in glioblastoma correlates with tumor progression and therapeutic resistance. These associations highlight its dual role as both a developmental regulator and a potential oncogenic factor.
Recombinant CHRDL1 is typically produced using mammalian expression systems to ensure proper post-translational modifications and folding. Its applications span basic research—such as studying BMP pathway dynamics in developmental biology—and preclinical studies exploring therapeutic strategies. For instance, recombinant CHRDL1 has been tested in models of neural injury to promote axon regeneration and in cancer to counteract BMP-driven metastasis. Challenges in its use include optimizing bioactivity stability and delivery methods for in vivo applications. Ongoing research aims to clarify its context-dependent roles and leverage its therapeutic potential in regenerative medicine and oncology.
×
